Home Blog of Signal Transduction GPCR & G Protein c-Kit ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

 

Leukemias, including acute myeloblastic leukemias, acute lymphoblastic lekemias (ALL), chronic myelogenous leukemia (CML), demonstrate significantly increased expression of Wilms tumor gene 1 protein (WT1), a zinc finger transcription factor. However, this potential therapeutic target is undruggable. Dubrovsky et al. developed an antibody, ESKM, which is therapeutically effective on acute and chronic leukemias in murine models. The article was published on Blood.

 

WT1 is an intracellular transcription factor, therefore, it is hard to be directly inhibited by small-molecule drugs or antibody therapies. Researchers established a human IgG1 T-cell receptor mimic (TCRm) monoclonal antibody called ESKM, which targets a 9-amino acid sequence of WT1, expressed in the context of cell surface HLA-A*02. They found ESKM is effective and not affected by gatekeeper resistance T315I. T315I is a mutation that inactivates  tyrosine kinase inhibitors (TKIs), which is a common uncurative therapy of Philadelphia chromosome-positive (Ph+) ALL. However, TKIs combined with ESKM is capable to cure mice Ph+ ALL. In addition, ESKM is specific to the leukemia cells, so it perform minimal effects to other cells. The findings suggested ESKM a promising nontoxic drug for PH+ leukemias.

 

Reference:
Blood. 2014 May 22;123(21):3296-304.

Related Products

Cat.No. Product Name Information
S1026 Imatinib Mesylate Imatinib Mesylate is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib Mesylate (STI571) induces autophagy.
S2475 Imatinib Imatinib is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib (STI571) induces autophagy.
S1021 Dasatinib Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
S1490 Ponatinib Ponatinib is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively. Ponatinib (AP24534) inhibits autophagy.
S8030 Plerixafor (AMD3100) Plerixafor (AMD3100, JM 3100, SID791) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor inhibits human immunodeficiency virus (HIV) replication.

Related Targets

c-Kit CXCR FGFR PDGFR VEGFR Bcr-Abl